Exagen Inc. (XGN)
Largest Insider Buys in Sector
XGN Stock Price History Chart
XGN Stock Performance
About Exagen Inc.
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Insider Activity of Exagen Inc.
Over the last 12 months, insiders at Exagen Inc. have bought $77,570 and sold $96,557 worth of Exagen Inc. stock.
On average, over the past 5 years, insiders at Exagen Inc. have bought $3.06M and sold $1.73M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ABALLI JOHN (President and CEO) — $77,570.
The last purchase of 40,401 shares for transaction amount of $77,570 was made by ABALLI JOHN (President and CEO) on 2024‑05‑16.
List of Insider Buy and Sell Transactions, Exagen Inc.
| 2024-05-16 | ABALLI JOHN | President and CEO | 40,401 0.2429% | $1.92 | $77,570 | +3.70% | ||
| 2024-03-04 | Sale | Adawi Kamal | CFO and Corporate Secretary | 12,784 0.0732% | $1.91 | $24,407 | -12.89% | |
| 2024-02-06 | Sale | Adawi Kamal | CFO and Corporate Secretary | 6,738 0.0337% | $1.95 | $13,133 | -6.97% | |
| 2023-10-17 | Sale | ABALLI JOHN | President and CEO | 33,819 0.1967% | $1.75 | $59,018 | +6.80% | |
| 2023-06-15 | TULLIS JAMES L L | 10 percent owner | 167 0.0009% | $3.11 | $519 | -38.98% | ||
| 2023-03-02 | Sale | Hazeltine Mark | Chief Business Officer | 3,667 – | $0 | $0 | +0.64% | |
| 2023-03-02 | Sale | Adawi Kamal | CFO and Corporate Secretary | 3,667 0.0209% | $2.30 | $8,432 | +0.64% | |
| 2023-02-08 | Sale | Hazeltine Mark | Chief Business Officer | 5,821 0.0336% | $2.69 | $15,672 | -11.36% | |
| 2023-02-08 | Sale | Adawi Kamal | CFO and Corporate Secretary | 5,821 0.0336% | $2.69 | $15,671 | -11.36% | |
| 2022-12-08 | ABALLI JOHN | President and CEO | 90,000 0.5494% | $2.68 | $241,200 | -2.72% | ||
| 2021-09-03 | Johnson Wendy S. | director | 1,000 0.006% | $14.02 | $14,020 | -39.78% | ||
| 2021-08-05 | Sale | TULLIS JAMES L L | director | 6,800 0.041% | $10.72 | $72,863 | -16.86% | |
| 2021-08-04 | Sale | TULLIS JAMES L L | director | 2,100 0.0124% | $11.39 | $23,917 | -22.91% | |
| 2021-08-03 | Sale | TULLIS JAMES L L | director | 4,300 0.0254% | $11.77 | $50,618 | -25.53% | |
| 2021-08-02 | Sale | TULLIS JAMES L L | director | 1,800 0.0104% | $11.92 | $21,454 | -28.04% | |
| 2021-06-29 | Sale | TULLIS JAMES L L | director | 5,379 0.0312% | $14.67 | $78,910 | -32.02% | |
| 2021-06-28 | Sale | TULLIS JAMES L L | director | 10,858 0.0647% | $14.98 | $162,696 | -30.88% | |
| 2021-06-25 | Sale | TULLIS JAMES L L | director | 8,763 0.0544% | $16.03 | $140,503 | -32.46% | |
| 2021-02-05 | Sale | TULLIS JAMES L L | 3,000 0.0214% | $17.00 | $51,000 | -27.32% | ||
| 2021-01-25 | Sale | Hunt Holdings Limited Partnership | 10 percent owner | 28,021 0.2168% | $16.01 | $448,616 | -14.63% |
Insider Historical Profitability
| ABALLI JOHN | President and CEO | 40401 2.4404% | $1.86 | 2 | 1 | <0.0001% |
| Adawi Kamal | CFO and Corporate Secretary | 243749 1.065% | $1.86 | 0 | 4 | |
| NMSIC Co-Investment Fund, L.P. | 10 percent owner | 2308958 13.5456% | $1.86 | 0 | 2 | |
| H.I.G. Bio-Exagen, L.P. | 10 percent owner | 1696252 9.9511% | $1.86 | 1 | 0 | <0.0001% |
| TULLIS JAMES L L | 10 percent owner | 1515839 8.8927% | $1.86 | 1 | 24 | <0.0001% |
| Hunt Holdings Limited Partnership | 10 percent owner | 1261324 7.3996% | $1.86 | 0 | 12 | |
| Hazeltine Mark | Chief Business Officer | 190205 1.1158% | $1.86 | 0 | 2 | |
| Johnson Wendy S. | director | 1000 0.0059% | $1.86 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RTW Investments, LP | $2.39M | 8.66 | 1.5M | 0% | +$0 | 0.04 | |
| Cowen Group | $1.43M | 5.17 | 898,630 | 0% | +$0 | 0.05 | |
| Wasatch Advisors | $1.25M | 4.53 | 786,895 | -7.46% | -$100,826.67 | 0.01 | |
| Silvercrest Asset Management Group Inc | $866,354.00 | 3.14 | 544,877 | 0% | +$0 | 0.01 | |
| Perkins Capital Management Inc | $785,000.00 | 2.84 | 493,571 | -3.01% | -$24,387.96 | 0.68 | |
| The Vanguard Group | $780,601.00 | 2.83 | 490,944 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $767,048.00 | 2.78 | 482,420 | -0.31% | -$2,385.00 | <0.0001 | |
| Stonepine Capital Management Llc | $611,514.00 | 2.21 | 384,600 | -42.57% | -$453,283.56 | 0.49 | |
| Geode Capital Management | $129,757.00 | 0.47 | 81,583 | 0% | +$0 | <0.0001 | |
| Penbrook Management Llc | $121,969.00 | 0.44 | 76,710 | +1.32% | +$1,590.00 | 0.08 | |
| Nantahala Capital Management Llc | $118,147.00 | 0.43 | 74,306 | -23.49% | -$36,280.76 | 0.01 | |
| UBS | $99,400.00 | 0.36 | 62,516 | +0.17% | +$170.13 | <0.0001 | |
| BlackRock | $88,253.00 | 0.32 | 55,505 | -4.03% | -$3,704.70 | <0.0001 | |
| Renaissance Technologies | $78,000.00 | 0.28 | 48,758 | +7.19% | +$5,231.14 | <0.0001 | |
| Bridgeway Capital Management | $64,872.00 | 0.24 | 40,800 | 0% | +$0 | <0.01 | |
| State Street | $44,029.00 | 0.16 | 27,691 | -17.81% | -$9,540.07 | <0.0001 | |
| Dimensional Fund Advisors | $42,035.00 | 0.15 | 26,437 | -26.63% | -$15,252.93 | <0.0001 | |
| Millennium Management LLC | $37,937.00 | 0.14 | 23,860 | +1.04% | +$389.55 | <0.0001 | |
| Prudential Financial | $31,482.00 | 0.11 | 19,800 | +86.79% | +$14,628.00 | <0.0001 | |
| Palumbo Wealth Management | $29,004.00 | 0.11 | 18,241 | New | +$29,004.00 | 0.01 | |
| Northern Trust | $26,029.00 | 0.09 | 16,370 | -0.43% | -$111.30 | <0.0001 | |
| First Bank & Trust | $21,494.00 | 0.08 | 13,518 | 0% | +$0 | 0.01 | |
| Citadel Advisors LLC | $11,512.00 | 0.04 | 7,240 | -65.08% | -$21,457.80 | <0.0001 | |
| Allworth Financial Lp | $11,154.00 | 0.04 | 7,015 | 0% | +$0 | <0.0001 | |
| Bank of America | $9,570.00 | 0.04 | 6,019 | -0.12% | -$11.13 | <0.0001 | |
| Barclays | $8,000.00 | 0.03 | 5,145 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $6,369.00 | 0.02 | 4,006 | -19.1% | -$1,504.01 | <0.0001 | |
| Wells Fargo | $3,906.00 | 0.01 | 2,457 | +0.04% | +$1.59 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 88 | -83.76% | -$0 | <0.0001 | |
| Qube Research & Technologies | $324.00 | <0.01 | 204 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $54.00 | <0.01 | 34 | +36% | +$14.29 | <0.0001 |